文献速递新发突发、热带与寄生虫病

抗疟药胎盘转运:卢美fantrine、甲氟喹与哌喹在母亲、新生儿及脐血中的浓度比较

Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究在分娩时采集接受青蒿琥酯-甲氟喹、蒿甲醚-卢美fantrine或双氢青蒿素-哌喹治疗无并发症疟疾后4-8周孕妇的母亲血、新生儿毛细血管血和脐血,比较药物浓度。结果显示药物在新生儿中可检测到,哌喹新生儿/母亲比值最高(几何均值0.98,95%CI 0.67-1.44),卢美fantrine和甲氟喹则低于母亲浓度一半。脐血浓度可能低估新生儿暴露,未来研究应考虑新生儿毛细血管采样。

要点

  • 脐血药物浓度低于新生儿毛细血管血,可能低估胎儿暴露。
  • 未观察到黄疸风险增加。

核心结论

  • 抗疟药经胎盘转运程度不一,新生儿浓度从低于母亲一半(卢美fantrine、甲氟喹)到接近母亲等效(哌喹)不等。

研究设计与样本

  • 在分娩时采集母亲血、新生儿毛细血管血和脐血的三联血样,对象为在分娩前4-8周因无并发症疟疾接受蒿甲醚-卢美fantrine、青蒿琥酯-甲氟喹或双氢青蒿素-哌喹治疗的90名孕妇(25例AL,29例ASMQ,36例DP)。

主要发现

  • 药物浓度在新生儿出生时可检测到,卢美fantrine、甲氟喹和哌喹首次给药后最长分别27、42和55天仍可检测。
  • 血药浓度母亲最高,新生儿次之,脐血最低。
  • 哌喹的新生儿/母亲比值最高(几何均值0.98,95%CI 0.67-1.44,n=32),其次为羧基甲氟喹(0.90,0.75-1.08,n=27)、去丁基卢美fantrine(0.44,0.30-0.65,n=16)、甲氟喹(0.42,0.38-0.47,n=26)和卢美fantrine(0.31,0.07-1.36,n=9)。
  • 母亲体重指数较高与去丁基卢美fantrine的新生儿/母亲比值较低相关;女性新生儿和给药后间隔较长与羧基甲氟喹的新生儿/母亲比值较高相关。
  • 未观察到黄疸风险增加。

关键数值与推荐

  • 哌喹新生儿/母亲比值几何均值0.98(95%CI 0.67-1.44,n=32)。
  • 羧基甲氟喹新生儿/母亲比值0.90(95%CI 0.75-1.08,n=27)。
  • 去丁基卢美fantrine新生儿/母亲比值0.44(95%CI 0.30-0.65,n=16)。
  • 甲氟喹新生儿/母亲比值0.42(95%CI 0.38-0.47,n=26)。
  • 卢美fantrine新生儿/母亲比值0.31(95%CI 0.07-1.36,n=9)。

临床怎么用

  • 对于孕期接受抗疟药治疗者,应了解不同药物胎盘转运程度差异,哌喹新生儿暴露接近母亲水平。
  • 脐血浓度可能低估新生儿药物暴露,未来研究可考虑采集新生儿毛细血管血。

局限性

  • 部分药物(如卢美fantrine)的新生儿/母亲比值样本量较小(n=9)。
  • 研究仅纳入分娩前4-8周接受治疗的无并发症疟疾孕妇,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria in pregnancy causes adverse effects on the mother and fetus, requiring effective antimalarial treatment. Understanding the transplacental transfer of antimalarials is vital to assessing fetal safety and the risk of congenital malaria. METHODS: We assessed a triad of blood samples (mother and neonatal capillary, cord) at delivery among women who were treated for uncomplicated malaria with artemether-lumefantrine (AL), artesunate-mefloquine (ASMQ), or dihydroartemisinin-piperaquine (DP) 4-8 weeks before delivery. RESULTS: Antimalarial drug concentrations at delivery were measured in 90 women (25 AL, 29 ASMQ, 36 DP). Drug concentrations were detectable in neonates at birth at a maximum of 27, 42, and 55 days after the first dose of lumefantrine, mefloquine, and piperaquine, respectively. The blood concentrations were highest in the mother, followed by the neonate, and lowest in cord blood. Piperaquine showed the highest neonate-to-mother (N/M) ratio (geometric mean, 0.98; 95% confidence interval, 0.67-1.44; n = 32) followed by carboxy-mefloquine (0.90; 0.75-1.08; n = 27), desbutyl-lumefantrine (0.44; 0.30-0.65; n = 16), mefloquine (0.42; 0.38-0.47; n = 26), and lumefantrine (0.31; 0.07-1.36; n = 9). Higher maternal body mass index was associated with a lower N/M ratio of desbutyl-lumefantrine. Female neonatal sex and a longer interval following drug administration were associated with higher N/M ratios of carboxy-mefloquine. No increased risk of jaundice was observed. CONCLUSIONS: Antimalarial drugs crossed the placenta variably. Neonatal concentrations ranged from less than half (lumefantrine, mefloquine) to near maternal equivalence (piperaquine). Collection of neonatal capillary samples at birth should be considered in future studies.SummaryWe compared antimalarial blood concentrations in mothers, neonates, and cords. Neonatal drug concentrations ranged from near maternal equivalence (piperaquine) to less than half (lumefantrine, mefloquine). Cord concentrations may underestimate neonatal exposure. Future studies should consider neonatal capillary sampling.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Saito M, Gilder ME, Carrara VI, et al. Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood. Clin Infect Dis. 2026. PMID: 41190558. doi:10.1093/cid/ciaf552

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。